AN2 Therapeutics (ANTX) news
Recent news
INEOS Energy $700M 5NC2 notes 9.25% area
INEOS Holdings Limited has announced the launch of a new offering of senior secured notes, reflecting the company’s ongoing efforts to manage its debt structure and optimize financial flexibility. The offering, led by its wholly owned subsidiary INEOS Finance plc, involves euro-denominated senior…
AInvest Wire · 15h agoAn2 Therapeutics - Gates Foundation funding supports advancement of boron-based leurs inhibitors for TB treatment
AInvest Wire · Sep 28, 2026An2 Therapeutics announces extension of funding for tuberculosis research collaboration with GSK
AInvest Wire · Sep 28, 2026An2 Therapeutics, Inc. reports inducement grants under listing rule 5635(C)(4)
AInvest Wire · Sep 16, 2026An2 Therapeutics reports positive enabling data
AN2 Therapeutics, Inc. (Nasdaq: ANTX) has reported positive enabling data for its boron chemistry platform, supporting the advancement of multiple programs into clinical development. The company highlighted progress across its pipeline, including the oral epetraborole program for polycythemia vera,…
AInvest Wire · Jun 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.